Replies to post #253166 on Biotech Values

[DewDiligence]

BGEN acquires APLS for $41.00/sh cash +CVR—a 140% premium to yesterday’s close (excluding the CVR):

https://www.globenewswire.com/news-release/2026/03/31/3265287/0/en/Biogen-to-Acquire-Apellis-Enhancing-the-Company-s-Growth-Portfolio-in-Immunology-and-Rare-Disease-Bolstering-Growth-Outlook-and-Accelerating-Expansion-into-Nephrology.html

The nominal deal value (excluding the CVR) is $5.6B.